Detalhe da pesquisa
1.
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Circulation
; 149(3): 192-203, 2024 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37632469
2.
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.
Diabetes Obes Metab
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38757725
3.
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
Eur Heart J
; 44(2): 129-138, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331326
4.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879424
5.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770629
6.
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
BMC Ophthalmol
; 23(1): 279, 2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37328736
7.
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Eur Heart J
; 43(48): 5047-5057, 2022 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36331315
8.
Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Eur Heart J
; 43(16): 1554-1565, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34922353
9.
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Curr Opin Lipidol
; 33(3): 147-159, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35695614
10.
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Circulation
; 143(11): 1109-1122, 2021 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33438437
11.
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.
Cardiovasc Drugs Ther
; 2022 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36550348
12.
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Circulation
; 141(20): 1608-1617, 2020 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223446
13.
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Circulation
; 141(8): 624-636, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707832
14.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med
; 379(22): 2097-2107, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403574
15.
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Cardiovasc Diabetol
; 20(1): 13, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33413345
16.
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Cardiovasc Diabetol
; 20(1): 125, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158057
17.
Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
Diabetes Obes Metab
; 23(1): 97-105, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32902128
18.
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Eur Heart J
; 41(42): 4114-4123, 2020 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32820320
19.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Eur Heart J
; 41(44): 4245-4255, 2020 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33051646
20.
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Eur Heart J
; 41(24): 2248-2258, 2020 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732742